PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsIanalumab
Ianalumab
Ianalumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target tumor necrosis factor ligand superfamily member 13B and tumor necrosis factor receptor superfamily member 13C.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
27 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Systemic lupus erythematosusD008180HP_0002725M32—13——4
Sjogren's syndromeD012859EFO_0000699M35.0—12——3
Thrombocytopenic purpura idiopathicD016553EFO_0007160D69.3——2——2
Autoimmune hepatitisD019693—K75.4—11——1
Lupus nephritisD008181EFO_0005761———1——1
Hemolytic anemia autoimmuneD000744EFO_1001264D59.10——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hidradenitis suppurativaD017497—L73.2—1———1
Idiopathic pulmonary fibrosisD054990—J84.112—1———1
Relapsing-remitting multiple sclerosisD020529EFO_0003929——1———1
PemphigusD010392EFO_1000749L10—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Rheumatoid arthritisD001172EFO_0000685M06.92————2
B-cell chronic lymphocytic leukemiaD015451—C91.12————2
Non-hodgkin lymphomaD008228—C85.91————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameIanalumab
INNianalumab
Description
Ianalumab (INN; development code VAY736) is a monoclonal antibody that is being investigated for autoimmune hepatitis, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Sjögren syndrome, and systemic lupus erythematosus.
Classification
Antibody
Drug classmonoclonal antibodies; narcotic agonists/antagonists (normorphine type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL4594357
ChEBI ID—
PubChem CID—
DrugBank—
UNII IDZN2GQ3II96 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
TNFSF13B
TNFSF13B
TNFRSF13C
TNFRSF13C
Organism
Homo sapiens
Gene name
TNFSF13B
Gene synonyms
BAFF, BLYS, TALL1, TNFSF20, ZTNF4
NCBI Gene ID
Protein name
tumor necrosis factor ligand superfamily member 13B
Protein synonyms
ApoL related ligand TALL-1, B lymphocyte stimulator, B-cell-activating factor, B-lymphocyte stimulator, BAFF, BLyS, CD257, delta BAFF, Delta4 BAFF, Dendritic cell-derived TNF-like molecule, epididymis secretory sperm binding protein, TALL-1, TNF and ApoL-related leukocyte expressed ligand 1, TNF homolog that activates apoptosis, TNF- and APOL-related leukocyte expressed ligand 1, tumor necrosis factor (ligand) superfamily, member 13b, tumor necrosis factor (ligand) superfamily, member 20, tumor necrosis factor ligand 7A, tumor necrosis factor superfamily member 13b, tumor necrosis factor-like protein ZTNF4
Uniprot ID
Mouse ortholog
Tnfsf13b (24099)
tumor necrosis factor ligand superfamily member 13B (Q9WU72)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 168 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use